Earnings Watch:

Octapharma Phase II/III trial for the targeted treatment of relapsing multiple sclerosis enrols first patients

Business Wire
Octapharma Phase II/III trial for the targeted treatment of relapsing multiple sclerosis enrols first patients
 
View Comments (0)